- A possible larger role for leading drug manufacturers, and the resulting opioid epidemic, is met with increased public and government demands for alternative therapies
- The Skinvisible and Quoin merger, with expected completion in 2018, will create an enterprise positioned to disrupt the $6 billion U.S. opioid market by producing and delivering non-opioid alternatives for pain management
- Quoin’s QRX001 is slated to provide alternative and effective pain management in the post-surgical setting, where 50 percent of opioid addictions start
A recent article by the Washington Post (http://cnw.fm/J40mp) addressed the opioid crisis, suggesting a larger role by leading pharmaceutical drug manufacturers than originally thought. The story alludes to the possibility that “drug manufacturers and distributors turned a willfully blind eye toward illegal drug trafficking.” In the midst of this, there is an opioid epidemic that has been deemed a national health emergency that results in 90 deaths per day (http://cnw.fm/7u9GF) and is growing exponentially, according to the Centers for Disease Control and Prevention.
There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed…
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com